Future clinical research with icodextrin-containing solutions

Peritoneal Dialysis International

Volumn 17, Issue SUPPL. 2, 1997, Pages

  Shockley, Ty R ^a   Wang, Tao ^b   Lindholm, Bengt ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical research; Early start dialysis; Glucose polymer; Icodextrin; Ultrafiltration

Indexed keywords

AMINO ACID; DEXTRAN 70; DEXTRIN; DIALYSIS FLUID; GLUCOSE POLYMER; SODIUM;

BLOOD CHEMISTRY; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIFFUSION; HUMAN; HYDROLYSIS; KIDNEY FAILURE; KIDNEY FUNCTION; MOLECULAR WEIGHT; PATIENT REFERRAL; PERITONEAL CAVITY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; ULTRAFILTRATION;

EID: 0030781443     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089701702s14     Document Type: Conference Paper

References (43)

1. Mistry CD, Gokal R, Mallick NP. Glucose polymer as an osmotic agent in CAPD. In: Maher JF, Winchester JF, eds. Frontiers in Peritoneal Dialysis. New York: Field, Rich, 1986; 241-8.
2. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2:178-82.
3. Winchester JF, Stegink LD, Gross AM, et al. Comparison of glucose polymer and dextrose as osmotic agents in CAPD. In: Maher JF, Winchester JF, eds. Frontiers in Peritoneal Dialysis. New York: Field, Rich, 1986; 231-40.
4. Higgins JT, Gross ML, Somani P. Patient tolerance and dialysis effectiveness of a glucose polymer-containing peritoneal dialysis solution. Perit Dial Bull, 1984; 4: S131-3.
5. Rubin J, Klein E, Jones Q, Planch A, Bower J. Evaluation of a polymer dialysate.Trans Am Soc Artif Intern Organs, 1983; 29:62-5.
6. Mistry CD, Gokal R, Peers EM, and the MIDAS study group. A randomized multicenter clinical trial comparing isosmolar Icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994; 46: 496-503.
7. Gokal R, Mistry CD, Peers E, and the MIDAS study group: A United Kingdom multicenter study oficodextrin in continuous ambulatory peritoneal dialysis.Perit Dial Int 1994; 14 (Suppl 2): S22-7.
8. Cooper A, Henderson IS, Jones MC. Daytime dwell with 7.5% icodextrin in automated peritoneal dialysis (APD). J EDTNA-ERCA 1995; 21 (Suppl 1):21.
9. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12:550-3.
10. Mistry CD, Gokal R. Can ultrafiltration occur with a hypo-osmolar solution in peritoneal dialysis?: The role for 'colloid' osmosis. Clin Sci 1993; 85(4):495-500.
11. Mistry CD, Bhowmick B, Ashman R, Uttley L. Clinical studies of new icodextrin formulations. Perit Dial Int 1994; 14 (Suppl 2):S55-7.
12. Mistry CD, Gokal R. Single daily overnight (12-h dwell) use of 7.5% glucose polymer (Mw 18700; Mn 7300) + 0.35% glucose solution: a 3-month study. Nephrol Dial Transplant 1993; 8:443-7.
13. Faller B, Shockley T, Genestier S, et al. A comparative clinical study of peritoneal dialysis solutions containing polyglucose and polyglucose in combination with amino acids. J Am Soc Nephrol 1995; 6(3):510.
14. Peers EM, Scrimgeour AC, Haycox AR. Cost-containment in CAPD patients with ultrafiltration failure. Clin Drug Invest 1995; 10:53-8.
15. Wilkie ME, Plant MJ, Edwards L, Brown CB. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafutration failure: Extension of CAPD technique survival. Pert Dial Int 1997; 17:84-6.
16. Peers EM, Scrimgeour AC. Icodextrin can prolong technique survival in CAPD patients with ultrafiltration failure. J Am Soc Nephrol September 1995; 6(3):513.
17. McArdle CS, Kerr DJ, O'Gorman P, et al. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 1994; 70: 762-6.
18. Millar DJ, Dawnay, AB. Glycation of albumin with icodextrin. J Am Soc Nephrol 1995; 6(3):551.
19. Millar DJ, Dawnay AB. Heat sterilization of PD fluid promotes advanced glycation end-product (AGE) formation. J Am Soc Nephrol 1995; 6(3):551.
20. Ho-dac-Pannekeet MM, Scheuten N, Langendijk M, et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50:979-86.
21. Ho-dac-Pannekeet MM, Imholz ALT, Struijk DG, et al. The standard peritoneal permeability analysis: A tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866-75.
22. Krediet RT, Struijk DG, Koomen DG, Arisz L. Peritoneal fluid kinetics during CAPD measured with intraperitoneal dextran 70. ASAIO Trans 1991; 37: 662-7.
23. Shockley TR, Ofsthun NJ. Pathways for fluid loss from the peritoneal cavity. Blood Purif 1992; 10:115-21.
24. Alsop RM. History, chemical, and pharmaceutical development of icodextrin. Perit Dial Int 1994; 14 (Suppl 2):S5-12.
25. Mistry CD, Gokal R. Icodextrin in peritoneal dialysis: early development and clinical use. Perit Dial Int 1994; 14 (Suppl 2):S13-21.
26. Davies DS. Kinetics of icodextrin. Perit Dial Int 1994; 14 (Suppl 2):S45-50.
27. Rubin J, Jones Q, Planch A, Bower J, Klein E. Substitution of a starch polymer for glucose in peritoneal dialysis. Nephron 1985; 39:40-6.
28. Rippe B, Stelin G, Ahlmen J. Lymph flow from the peritoneal cavity in CAPD patients. In: Maher JF, Winchester JF, eds. Frontiers in Peritoneal Dialysis. New York: Field, Rich, 1986; 24-30.
29. Mactier RA, Khanna R. Absorption of fluid and solutes from the peritoneal cavity: Theoretic and therapeutic implications and applications. ASAIO Trans 1989; 35: 122-31.
30. Wang T, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Increased peritoneal permeability in CAPD results in decreased fluid and small solute removal, and lower survival. J Am Soc Nephrol 1996; 7:1468.
31. Wang T, Heimbürger O, Chen C, Bergström J, Lindholm B. Fluid removal by polyglucose solution is not simple as we thought (Abstract). 14th ISN congress, Sydney, Australia, 1997.
32. Flessner M, Schwab A. Pressure threshold for fluid loss from the peritoneal cavity. Am J Physiol 1996; 270: F377-90.
33. Gokal R. Osmotic agents in peritoneal dialysis. Contrib Nephrol 1990; 85:126-33.
34. Hull AR, It's time for a paradigm shift in nephrology. Neph News and Issues 1996; 10:26-7.
35. Tattersall J, Greenwood R, Farrington K. Urea kinetics and when to commence dialysis. Am J Nephrol 1995; 15:283-9.
36. Campbell JD, Ewingman B, Hosokawa M, Van Stone JC. The timing of referral patients with end-stage renal disease. Dial Transplant 1989; 18:660-8.
37. Hakim RM, Lazarus JM. Initiation of dialysis. J Amer Soc Nephrol 1995; 6:1319-28.
38. Jungers P, Zingraff J, Albouze G, et al. Late referral to maintenance dialysis: Detrimental consequences. Nephrol Dial Transplant 1993; 8:1089-93.
39. Innes A, Rowe PA, Burden RP, Morgan AG. Early deaths on renal replacement therapy: The need for early nephrological referral. Nephrol Dial Transplant 1992; 7:467-71.
40. Ratcliffe PJ, Phillips RE, Oliver DO. Late referral for maintenance dialysis. Br Med J 1984; 288:441-3.
41. Khan IH, Catto GRD, Edward N, MacLeod AM. Chronic renal failure: Factors influencing nephrology referral. Quart J Med 1994; 87:559-64.
42. de Fijter CWH, Verbrugh HA, Oe PL,et al. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 21:411-8.
43. Thomas S, Schenk U, Fischer F-P, et al. In Vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis 1997; 29:246-53.